MedTrace Logo

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet

NCT00954304 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-09-13

No results posted yet for this study

Summary

The purposes of this study are to investigate the duration of P-glycoprotein inhibition after oral administration of HM30181AK tablet in healthy male subject and proper dose of HM30181AK tablet.

Conditions

  • Healthy

Interventions

DRUG

HM30181AK 1mg

HM30181AK 1mg tablet

DRUG

HM30181AK 5mg

HM30181AK 5mg tablet

DRUG

HM30181AK 15mg

HM30181AK 15mg tablet

DRUG

HM30181AK 60mg

HM30181AK 60mg tablet

DRUG

Loperamide 2mg

Loperamide 2mg capsule

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu, MD., Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954304 on ClinicalTrials.gov